Chloe Kent
Senior Reporter
Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.
Latest From Chloe Kent
Insitro’s Daphne Koller On The Marriage Of Biology And Machine Learning At The Company’s Heart
Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.
BioFactura Completes Phase I For Late-To-Market Stelara Biosimilar
BioFactura has completed a successful Phase I trial of its Stelara (ustekinumab) biosimilar BFI-751, which is expected to file in developed markets in 2026.
Generics Industry Preps For Potential Entry Of Ukraine Into EU
Generics industry trade group Medicines for Europe has met with Ukrainian government officials to discuss how to plan for any future integration process.
Adcock Remains Resilient In Tough Business Environment
Adcock saw its profits grow by 4.2% during FY 2024 despite a challenging economic environment.
Aspen Appears Unfazed As Potential Difficulties Loom
Analysts posted wary notes about the prospects of South African pharmaceutical firm Aspen as its financial year came to an end, while management maintained confidence in the firm’s “solid results.”
Cimerli Success Drives Strong H1 At Formycon
Formycon delivered a strong H1, as its Lucentis biosimilar made significant strides in the US market. The company now anticipates the highest revenue in its history for 2023.